Heron Therapeutics (HRTX) delivered earnings and revenue surprises of 9.52% and 25.36%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:00 p.m. ET at the Lotte New York Palace hotel.

Heron Therapeutics (HRTX) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Heron Therapeutics (HRTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that it has initiated a Phase 1b/2 clinical study in patients undergoing bunionectomy of HTX-034, Heron's next-generation product for the treatment of postoperative pain. The study initiation follows clearance from the U.S. Food and Drug Administration (FDA) of Heron's Investigational New Drug application for HTX-034 for the treatment of postoperative pain.

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But when you pick a...

If you own shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) then it's worth thinking about how it contributes to the...

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three months ended March 31, 2020 and highlighted recent corporate updates.

AbbVie, Adverum Biotechnologies, and Heron Therapeutics could all be gearing up for a strong May. Here's why.

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that Barry Quart, Pharm.D., President and Chief Executive Officer of Heron Therapeutics, will present at the 19th Annual Needham Virtual Healthcare Conference on Tuesday, April 14th, 2020 at 2:50 p.m. ET. The conference is being held in a virtual format.

Heron Therapeutics (HRTX) delivered earnings and revenue surprises of -12.07% and 0.81%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week highs on Feb. 19) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Akebia ...

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced financial results for the three and twelve months ended December 31, 2019 and highlighted recent corporate updates.

Heron Therapeutics, Inc. (NASDAQ:HRTX) just released its latest quarterly results and things are looking bullish. The...

The Zacks Analyst Blog Highlights: Moderna, Incyte, Heron Therapeutics and NGM Biopharmaceuticals

A stock can experience a pullback for a variety of reasons, be it disappointing quarterly results, the impact of internal politics, or the effect of the coronavirus on the economy. Yet, traditionally, those with strong fundamentals will bounce back and be propelled upwards again. As the pros will tell you, the best play in the investing game is to seek out the promising names when they’re beaten down as opposed to when they’re already moon bound. Or as industry parlance has it, to “buy the weakness.”With this in mind, we set out to put this maxim to work. Using TipRanks’ Stock Screener, we found three stocks that have experienced a recent pullback but which the analysts think are ripe for a turnaround. What’s more, according to the data crunching tool, all currently boast a Strong Buy consensus rating from the Street.Builders Firstsource (BLDR)There’s no beating about the bush here. Builders Firstsource does what it says on the tin; the Dallas, Texas based company manufactures and supplies building materials, and is the US’s largest supplier of building products and prefabricated components.BLDR had an outstanding 2019; boosted by consistent earnings beats, the stock appreciated by 138% throughout the year. In the last week, though, sentiment has turned bearish and BLDR stock has tumbled by 17%.The drop came following the release of BLDR’s latest earnings results. BLDR's F4Q19 EBITDA came in at the high end of management's guidance ($109.3 million), along with gross margin exceeding expectations, whilst the -2.9% sales comp was within the company’s -2% to -5% guide.According to Wedbush’s Jay McCanless, there are reasons for investors’ disappointment: “We believe a continuing EPS number of $0.31 (excludes an ~$0.04/share tax benefit from a 13% tax rate versus the 25% we expected) versus the F4Q19 Thomson consensus estimate of $0.33 may be one explanation. Another may be the 60bp Y/Y increase in BLDR's SG&A/sales ratio to 22.8% which was 80bp above the consensus estimate,” said the 4-star analyst.Nevertheless, McCanless notes “the key metrics beat our forecasts and we would buy on any weakness.” Accordingly, McCanless reiterated an Outperform on BLDR, along with a price target of $29. The implication for investors? Potential upside of 38%. (To watch McCanless’s track record, click here)Overall, the Street is with the bulls on Builders. 8 Buys and 1 Hold add up to a Strong Buy consensus rating. At $30.88, the average price target implies possible gains of 33% in the year ahead. (See BLDR stock analysis on TipRanks)Heron Therapeutics (HRTX)From builders to biotechs, where we encounter Heron Therapeutics. This San Diego small-cap develops treatments to address unmet medical needs, with a focus on patients suffering from cancer or postoperative pain. Year-to-date, Heron stock is down by 21%.Heron is currently waiting for approval from the FDA on its experimental post-operative pain medication HTX-011. The FDA recently extended the review period for the drug by up to three months. The PDUFA date is now June 26, 2020, but the regulator has indicated the review may be completed sooner.The announcement of the delay was accompanied by a positive update. The FDA has recommended that the manufacturing site for HTX-011 should be approved by the inspector. To recall: Last May, HTX-011 was rejected by the FDA not because of clinical or safety issues, but on account of a lack of Chemistry, Manufacturing and Controls (CMC) data.Cowen’s Boris Peaker believes the delay is just a minor setback. The 4-star analyst expects approval for HTX-11, and also recommends to “buy the stock on weakness.”Peaker further added, “We are not changing the long-term outlook for HTX-011 in our model and anticipate only an incremental delay in the launch date without an impact on competitive positioning of this drug. We continue to believe that Heron is in a strong position to launch HTX011 with~ $390MM in cash and investments at YE19 and we model operating cash burn of ~$120MM in 2020. The company has sufficient capital to maintain pre-launch activities ahead of the new PDUFA date.”Accordingly, Peaker kept his Outperform rating as is, with the price target remaining at $40. This conveys his confidence in Heron adding 115% to the share price over the next 12 months. (To watch Peaker’s track record, click here)Overall, a full set of Buys – 7, as it happens – means HRTX currently hold a Strong Buy consensus rating. The analysts see the biotech gaining 104% this year, should the average price target of $37.83 be met in the year ahead. (See Heron stock analysis on TipRanks)Lithia Motors (LAD)Lithia Motors has built its way up to become one of the US’s largest car retailers. The company has been on a shopping spree and the constant expansion means it is now the third largest automotive retailer in the country. Only last week, Lithia announced that it had acquired two Lexus stores in Sacramento and Roseville, California. The company has also been receiving plaudits from its peers; yesterday it was announced that twenty-eight Lithia Motors stores have been awarded 2020 Dealer of the Year by DealerRater, a leading car dealership reviewer.The growth was mirrored by an excellent market performance in 2019, with 95% added to the share price over the year. Year-to-date, though, LAD stock is down by 15%.The company’s recent earnings results were mostly in-line with expectations. Revenue of $3.27 billion, indicated 10.1% year-over-year growth and beat the estimate by $50 million, although at $2.95 the company slightly missed on EPS by $0.02.Despite the decent quarter, shares dropped following the report’s release. J.P. Morgan’s Rajat Gupta believes there’s a simple explanation. The analyst notes the well above-average growth metrics were not like the strong beats seen at peers. According to Gupta, though, the drop is an opportunity to snap up shares at a discount.“We would treat any weakness in the stock as a buying opportunity, as we continue to see room for upward revisions to forward estimates with further upside from capital deployment,” he added.Bottom line, Gupta’s Overweight rating stays put along with the $175 price target. The figure implies possible upside of 40%. (To watch Gupta’s track record, click here)The Street revs up its engine in agreement. All 4 analysts tracked over the last 3 months agree Lithia is a Buy. Accordingly, Lithia has a Strong Buy consensus rating. The average price target of $164.75, indicates potential gains of 33% from current levels. (See Lithia stock analysis on TipRanks)

The biotech sector was in focus with pipeline updates from a few small biotech companies.

Despite COVID-19's devastating impact, one legendary stock picker might have just cracked the market code. While the broader market tumbled, investing firm Renaissance Technologies and its founder Jim Simons could mark 2020 as a year of record-smashing growth. Since the start of this year through April 14, the firm’s core Medalian hedge fund notched a 24% gain.So, how has Simons managed to do it? When the professor and mathematician left the world of academia and launched Renaissance in 1982, he fundamentally changed the investing process, pioneering a new quantitative approach that relies on algorithms to uncover patterns in the market. Using this strategy, the firm has become one of the best-performing quant shops on the Street.Traditional methods like relying on intuition, speaking with companies and analyzing balance sheets didn’t stand a chance against Simons and his computer models. Medallion has returned 66% per year, or 39% after fees, since 1998, leaving other gurus like Warren Buffet and Ray Dalio in the dust. While Simons, who is now worth an estimated $23 billion, remains active at the firm but doesn’t directly oversee the fund anymore, he is in a league of his own, and is considered one of the all-time investing greats.Looking at Renaissance’s recent activity as a starting point, we poured through its latest 13F filing in an attempt to find compelling opportunities among its purchases. Narrowing in on three healthcare stocks, TipRanks’ database revealed that each is also admired by the analyst community, enough so to earn a “Strong Buy” consensus rating. It doesn’t hurt that all three sport some serious upside potential as well. Durect Corporation (DRRX)Using its endogenous epigenetic regulator program, Durect develops innovative treatments for acute organ injuries and chronic liver diseases. While it has experienced a pullback recently, some believe the weakness presents a buying opportunity. Among the bulls is Simons’ firm. In the last quarter, Renaissance gave its DRRX holding a boost when it added 989,000 shares. Its new position, which now lands at 5,208,212 shares, is valued at $8,073,000.Turning now to the Wall Street analysts, several take an optimistic approach when it comes to DRRX, including B.Riley FBR’s Mayank Mamtani. To back up his bullish thesis, the five-star analyst cites management’s update on the progress of lead development candidate, DUR-928, an epigenetic modulator. According to the company’s announcement, it’s collaborating with the FDA to study DUR-928 in a Phase 2 clinical trial involving COVID-19 patients in the hospital with acute organ injury.In preclinical studies, DUR-928 has already been able to stabilize mitochondria, modulate inflammatory responses and promote cell survival and tissue regeneration. Additionally, Mamtani points out that the candidate “may play an important role for up to half of hospitalized patients with COVID-19 reported to have had elevated liver enzyme levels, indicative of liver injury and more than a third of hospitalized patients reported to have kidney damage.” He added, “We are encouraged by DRRX's commitment to leverage DUR-928's unique mechanism to help combat the public health crisis, with an incremental cost of ~$3 million that has relatively limited impact on cash runway.” That being said, DUR-928's potential extends beyond COVID-19. Enrollment for the Phase 1b open label NASH program has been completed, with top-line data slated for release in Q2. The company has also been ramping up preparations to initiate a Phase 2b program for IV-administered DUR-928 in severe alcoholic hepatitis (AH) patients. These preparations include reaching an agreement on trial design and key study endpoints with the FDA. It should be noted that enrollment is now expected to begin in the second half of 2020 thanks to COVID-19-related impacts.As for its other candidate, POSIMIR, the company is currently managing information requests (IRs) regarding the NDA review. Mamtani thinks this “suggests an active engagement of agency in the review process.”Taking into account everything DRRX has to offer, Mamtani stated, “Given the recent pullback, we find both an undervalued AH opportunity and NT catalysts in top-line Phase 1b NASH results and the POSIMIR decision to offer an additional attractive entry point for DRRX shares.”To this end, Mamtani left a Buy rating and $5 price target on the stock. Should this target be met, a twelve-month gain of 100% could be in store. (To watch Mamtani’s track record, click here)Do other analysts agree with Mamtani? It turns out that they do. With 100% Street support, or 3 Buy ratings to be exact, the message is clear: DRRX is a Strong Buy. At $5.25, the average price target implies 110% upside potential. (See Durect stock analysis on TipRanks)Heron Therapeutics (HRTX)By applying innovative science and technologies with well-known pharmacology, Heron hopes to develop patient-focused solutions that address unmet medical needs. While HRTX did receive a CRL regarding its HTX-011 product, some believe it has the potential to be a best-in-class drug for post-operative pain.One of its fans is Renaissance. The billionaire’s fund snapped up 870,892 shares, increasing its HRTX holding by a whopping 482%. As for the new value of Renaissance’s position, it comes in at over $12.3 million.Wall Street analysts also have good things to say about HRTX. Representing Leerink, analyst Ami Fadia notes that HTX-011 review is on track for the June 26 PDUFA date, based on HRTX’s recent conversation with the FDA. Management also stated that the FDA communications suggest things are progressing well, with label discussions not expected to kick off before early June. With respect to HTX-011's CE marking in the EU, there will be a delay as a result of COVID-19, but management thinks the decision could come in the second half of 2020 and that the device shouldn’t encounter any review issues.Calling the HTX-011 growth opportunity underappreciated, Fadia argues “HTX-011's potential is supported by the strong pain reduction, safety, and opioid-sparing data from the Phase 3, and the total knee arthroplasty (TKA) and breast augmentation nerve block Phase 2b data.” She added, “We believe management has taken the appropriate steps to resolve the issues in the CRL, the additional three-month delay is not reflective of additional issues specific to HTX-011, and management can get approval by the June 26, 2020, PDUFA date.”On top of this, COVID-19 has had a relatively limited impact on Cinvanti sales, and the asset has held up well as arbitrage progresses. “Management remains confident in growth back in the franchise starting 2021, recapturing not only the clinic share lost during the arbitrage period but also continuing to gain share among those clinics that have been waiting until post arbitrage before adopting Cinvanti,” Fadia said.Bearing this in mind, Fadia stayed with the bulls. Along with an Outperform call, she reiterated the $26 price target. This target conveys her confidence in HRTX’s ability to climb 64% higher in the next year. (To watch Fadia’s track record, click here)With only Buy ratings assigned in the last three months, 6 to be exact, the consensus is unanimous: HRTX is a Strong Buy. In addition, the $38 average price target is more aggressive than Fadia’s and implies 136% upside potential. (See Heron stock analysis on TipRanks)Aurinia Pharmaceuticals (AUPH)Last up to bat, we have Aurinia, which wants to transform the way autoimmune diseases are treated. As its Voclosporin therapy represents a huge opportunity, Wall Street is getting behind this healthcare company.Simons’ firm didn’t miss out on an opportunity to tack on more shares to its AUPH holding. Renaissance bought up 860,266 shares, bringing its total stake in the company to 1,438,800 shares. After the position was bumped up by 149%, the new value is $20.9 million.Meanwhile, Cowen analyst Ken Cacciatore also likes what he’s seeing. He points out that the rolling NDA submission for Voclosporin, a next-generation calcineurin inhibitor that blocks IL-2 expression and T-cell mediated immune responses, in lupus nephritis (LN) is moving right on track, and should be completed by the end of Q2. This means that an approval could potentially come in the first half of 2021. “Our conviction in this management team and opportunity remains unchanged. This asset is still materially discounted at this valuation level, in our view,” he commented.According to Cacciatore, the robust results from the Phase 3 AURORA study “confirmed Voclosporin’s safety profile, clarifying the prior imbalance in deaths from the low-dose Voclosporin arm in Phase 2.” The analyst added, “Based on these results, and given the unmet need and significant market opportunity in LN, we believe Voclosporin could easily reach $1 billion-plus in this indication alone.”When it comes to AUPH’s intellectual property, Cacciatore thinks it is strong enough to enable more durability than others might expect. Expounding on this, he said, “Specifically, our legal consultants believe the patent claim of dose adjustments based on eGFR – and the unexpected findings of potentially improved efficacy at those lowered optimized doses – appears solid and defendable (after a full review of the prosecution history). And we believe the Voclosporin label will include language describing these findings/instructions, meaning generics would infringe.”Based on the clear pathway to approval for Voclosporin, most likely via a priority review, and the strength of its intellectual property, the deal is sealed for Cacciatore. As a result, he maintained an Outperform rating and $30 price target. Given this target, shares could rise 77% in the next twelve months. (To watch Cacciatore’s track record, click here)As for other analysts, it turns out that they have also been impressed. 6 Buys and no Holds or Sells have been received in the last three months, making the consensus rating a Strong Buy. A twelve-month gain of 52% could be in the cards if the $25.80 average price target is met. (See Aurinia stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...